Latest Natural Health News

The AMA’s Peptide Crackdown: A Smoking Gun for Big Pharma’s Influence

The AMA’s Peptide Crackdown: A Smoking Gun for Big Pharma’s Influence
Share This Article

As HHS moves to expand access to life-saving peptides, the American Medical Association is demanding a rollback. Patients deserve choice over sweeping warnings from an organization whose tentacles reach deep into Big Pharma. Action Alert!

Listen to the audio version of this article:


THE TOPLINE

  • HHS is opening a pathway for six peptides with safeguards for prescribing, ingredient testing, and adverse event reporting. The AMA wants that pathway withdrawn and is pressing for stronger enforcement.
  • Congress created a separate pathway for qualifying compounded medicines. Yet the AMA and the FDA keep insisting that peptides and other compounded medicines be held to the same standards as licensed drugs.
  • Major drugmakers have contributed to the AMA Foundation, creating a massive conflict of interest. Nearly half of AMA members are medical students or physicians in training, calling into question how representative the AMA is.

The American Medical Association (AMA) wants the federal government to take treatment options away from you.

Just as the Department of Health and Human Services is opening a pathway for access to certain compounded peptides, the AMA is demanding that the government reverse course. Its new policy calls for rescinding measures that ease restrictions on compounded peptides. Its November 13 advocacy update also announces plans to push medical and pharmacy boards toward enforcement against pharmacies, telehealth platforms, and online dispensaries distributing these products.

That is an extraordinary response to a policy designed to bring patients into a more controlled system of care rather than an online grey market with products of questionable quality. The AMA’s position becomes less surprising when we consider, as we will below, the substantial ties between the AMA and the pharmaceutical industry that benefits when patients lose options and become more reliant on drugs.

ANH supports expanded access to peptides through qualified practitioners and pharmacies. We believe patients deserve an honest assessment of the evidence and the freedom to make informed decisions with their doctors. The AMA’s sweeping approach threatens both.

“Not FDA Approved” Does Not Settle the Argument

The AMA emphasizes that these peptides have not undergone the testing required for FDA-approved drugs. But Congress deliberately created a separate legal pathway that exempts qualifying compounded medicines from the new drug approval process. The FDA has deployed similar reasoning against compounded bioidentical hormones: these medicines lack FDA approval, so their safety and effectiveness remain unproven. Of course, they omit to say that compounded medicines are subject to stringent quality standards and state pharmacy rules. Their argument is also circular. It treats the absence of approval as grounds for restricting access to medicines that Congress expressly allowed to be provided without that approval. The proper question is what the available evidence shows about a particular treatment’s benefits and risks—not whether it has passed through a process the law does not require.

Potential Risks Are Not Proof of Widespread Harm

Peptide safety deserves serious scrutiny. That scrutiny must also distinguish demonstrated harm from theoretical concerns and missing information.

The FDA’s explanations for restrictions on several peptides repeatedly invoke potential immune reactions, aggregation, impurities, and insufficient safety data. But as we’ve said, the absence of data does not imply risk, and it is certainly not enough to warrant blanket restrictions.

Thymosin alpha-1 offers a particularly revealing example. FDA’s own review found that, in most clinical studies, it was well tolerated and was not associated with significant adverse events. In our view, these safety arguments are a smokescreen.

Follow the Financial Relationships

So why is the AMA really doing this? As is so often the case, one need only follow the money. In the AMA’s case, the trail leads right to Big Pharma.

The AMA Foundation’s donor disclosures list Pfizer in its category of donors that have contributed at least $1 million over their lifetimes. AstraZeneca, Eli Lilly, Genentech, Merck, and the DC-based pharma trade association, Pharmaceutical Research and Manufacturers of America (PhRMA) appear in the $500,000–$999,999 category. Its 2026 Industry Roundtable includes PhRMA at the $50,000-or-more level and companies including Lilly, Merck, Amgen, Moderna, and Sanofi at the $30,000–$50,000 level.

The AMA also receives publishing revenue from advertising and reprints, among other sources. Its historical relationship with pharmaceutical advertising is well documented, including in federal litigation describing drug companies as the principal purchasers of advertising in its periodicals. Its current annual report does not establish how much of its advertising revenue comes specifically from pharmaceutical companies.

The economic incentive is straightforward: to the extent compounded treatments offer alternatives to commercially manufactured drugs, restricting those alternatives can protect drug monopolies.

ANH has previously challenged the AMA’s commercial interests, including its lucrative role in medical billing codes. The broader concern remains: an organization embedded in the business of conventional medicine should not receive an automatic presumption that its preferred restrictions serve patients.

The AMA Does Not Speak for Every Doctor

The AMA’s political authority also exceeds what its membership figures alone can justify.

In the early 1950s, approximately 75 percent of American physicians belonged to the association. By 2011, it’s been estimated that roughly 15 percent of practicing U.S. physicians belonged when student and resident members were excluded. Membership has since recovered: the AMA’s 2025 annual report records approximately 322,000 members.

But the composition matters. The AMA’s December 2024 demographic figures show that medical students accounted for 18.2 percent of members and residents, interns, and fellows for another 29.2 percent—nearly half combined. These figures do not suggest that the AMA is representative of independently practicing doctors.

Lawmakers should hear directly from physicians who prescribe peptides, pharmacists who prepare them, researchers studying them, and patients whose options would be affected.

Patients Deserve a Better Standard

Patients deserve protection from unsafe products. They also deserve protection from policies that unnecessarily take treatment decisions out of their hands.

Action Alert!

Leave a Reply

Your email address will not be published. Required fields are marked *


Related Posts